

CURRICULUM VITAE

Tünde CSÉPÁNY, MD, PhD

Personal data:

Born: May 28, 1956, Hungary.
Married: László Mátyus (1980-);
Children: László (1982)

Education:

University Medical School of
Debrecen, Hungary. 1974-1980.

Work place: University of Debrecen, Faculty of
Medicine, Department of Neurology, Neurology Clinic
Moricz Zs. crt. 22.
Debrecen
4032 HUNGARY
Tel: +3652411600/54202
Fax: +3652453590
email: csepany@med.unideb.hu



Present position: Associate Professor, Department of Neurology, University of
Debrecen (2004-)

Board certification:

Neurology (1984)
Psychiatry (1990)

Degrees:

M.D. - University Medical School of Debrecen, 1980.
Ph.D. - Medical Science (Immunology), University Medical School of
Debrecen, 1997.

Language:

Intermediate level oral and written exam in English, 1986

Positions:

1980-1984 Resident, Department of Neurology and Psychiatry, University Medical School
of Debrecen
1984-1992 Assistant Lecturer, Department of Neurology and Psychiatry, University
Medical School of Debrecen
1986-1988 Postdoctoral Fellow, The Johns Hopkins University, Department of Biology,
Baltimore
1989 Visiting Scientist, The Johns Hopkins University, Department of Biology,
Baltimore
1992-2004 Assistant Professor, Department of Neurology and Psychiatry, University
Medical School of Debrecen
1992-1995 Head of Stroke Unit, Department of Neurology and Psychiatry, University
Medical School of Debrecen

1995-1996 Head of Neuroimmunology Unit, Department of Neurology, University Medical School of Debrecen
1996-present Head of Neurology Ward, Department of Neurology, University of Debrecen

Awards: Award for Excellency in Stroke Research (1994)
Pro Scientia Tutorial Award (1997)
Award for Outstanding Intellectual Achievement of the Year, PTE (2006)
Award for Scrupulous and Outstanding Work, DEOEC (2008)
“Teacher of the year” award based on the votes of medical students in 2011
Commemorative silver medal for long standing tutorial activity awarded on the XXXth National Student Congress (2011)
Award for Scrupulous and Outstanding Work, DE (2014)

Societies:

President of the Hungarian Neuroimmunology Society 2013-
Treasurer of the Hungarian Neurological Society (2011-2015)
Secretary General of the Hungarian Neurological Society (2015-)
President of the National Advisory Board for Multiple Sclerosis (2009-2012)
Council member ofECTRIMS (European Committee for Treatment and Research in Multiple Sclerosis) 2005-2011 and 2014-
Member of Central European Tysabri Advisory Board (2011-)

Co-investigator in multicenter clinical trials:

Safety and tolerability of copolymer-1 in patients with relapsing-remitting MS (Phase IV.)
Safety and tolerability of interferon beta 1b-Mannitol in patients with relapsing-remitting MS (Phase III.)
Safety, tolerability, and efficacy of interferon beta 1b in patients with a first demyelinating event suggestive of MS (Phase III. BENEFIT)
Safety and efficacy of Natalizumab with subjects with relapsing-remitting MS (Phase III. AFFIRM)
Safety of long term Natalizumab with subjects with relapsing-remitting MS (101-MS-321)
Efficacy and safety of BG00012 in subjects with relapsing-remitting MS (Phase II. C1900)
Efficacy and safety of human monoclonal antibody CNTO 12 in subjects with relapsing-remitting MS (Phase II. CENTOCOR)
Double-blind, randomized, multicenter, parallel-group study comparing efficacy and safety of FTY720 1.25 mg and 0.5 mg administered orally once daily versus Avonex in patients with relapsing-remitting multiple sclerosis (Phase III. Novartis)
Multicenter, Double-Blind, Placebo-Controlled, Dose Ranging Study to determine the Safety and Efficacy of Daclizumab HYP (DAC-HYP) as a Monotherapy in subjects with RRMS 205-MS-201 (Phase II. SELECT) and Extension study (205-MS-202 Phase II: SELECTION), Open-label Extension 205-MS-203.
Multicenter, double-blind, randomized, adaptive dose-ranging, placebo-controlled, parallel-group study evaluating safety, tolerability and efficacy on MRI lesion parameters and determining the dose response curve of BAF312 given orally once daily in patients with RRMS (Phase II.) and extension.

Multicenter, double-blind, randomized, placebo-controlled, parallel-group study comparing the efficacy and safety of 0.5 mg FTY720 administered orally once daily versus placebo in patients with PPMS

Scientific interest:

Src gene and infectivity of retroviruses.

Neurological symptoms and early diagnosis of neurological involvement in systemic autoimmune disorders (non-invasive cerebrovascular, cerebral metabolism).

Cerebrovascular diseases in young adults.

Treatment of multiple sclerosis.

Books: 2

Book chapters: 32

Peer reviewed papers: 44

In extenso IF: 73,851

Citation: 496

HI: 11

GCP course: December 2013 – Debrecen, HUNGARY